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TUBERCULOUS MENINGITIS IN CHILDREN*
THE ADDITION OF FORTY-ONE PROVEN CASES
A CRITICAL ANALYSIS OF THE LITERATURE DEALING WITH STREPTOMYCIN
THERAPY SINCE ITS INTRODUCTION
ROBERT W. SAPPENFIELD,** VERNE G. ROBINSON,t
AND DWAIN N. WALCHERtII
In January, 1944, Schatz, Bugie, and Waksman' reported the isolation
of a new antibacterial substance which was designated as streptomycin. In
December, 1944, Feldman and Hinshaw' reported their observations on the
suppressive effect of streptomycin on the human variety of microbacterium
tuberculosis in guinea pigs. In January, 1946, Cooke, Dunphy, and Blake'
reported in this Journal the first human case of tuberculous meningitis
treated with streptomycin. At the time the article was published the patient
had been observed for four months after therapy had been discontinued.
She is still alive six years after the first therapy was given, she has had no
relapses, and has received no further streptomycin after the initial 68 days
of treatment.n
From January 1, 1947, to January 1, 1951, fifty-six patients on whom a
clinical diagnosis of tuberculous meningitis was made were seen at this
hospital. This diagnosis was bacteriologically proven on thirty-seven
patients who were treated, and the series is reported in detail (Table 1).
An additional five were proven but died before receiving treatment, and
fourteen had strong supporting evidence for the diagnosis of tuberculous
meningitis, but the spinal fluid proof could not be obtained.
As the data were analyzed certain observations merited comment, namely,
age of the patient, length of illness prior to admission to the hospital, the
clinical status of the patient when therapy was started, latent period prior
to institution oftherapy, and the presence or absence of miliary tuberculosis.
Twenty (54%o) of the patients were two years of age or under. Of these,
sixteen (80%o) were ill for two weeks or more; thirteen (65%o) were con-
sidered late, i.e., semicomatose or comatose, in the disease when therapy
was started; twelve (60%o) had miliary tuberculosis. All twenty patients
had one or more of these factors complicating their illness; all of these
patients died.
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When these figures were compared with some observations obtained for
the seventeen children over two years of age, a striking contrast was
obtained. Eight (47%) were ill for two weeks or more, a difference of
33%o; nine (53%o) were late in the disease when therapy was started, a
difference of 12%o; only three (18%o) had miliary tuberculosis, a difference
of 42%o in miliary tuberculosis. The four living patients are in this group.
Lincoln'M states that prior to streptomycin therapy the longest duration of
tuberculous meningitis from the time of onset until death was 63 days, with
the average being 19Y2 days. In a recent review of sixty-six cases LorberM
found that the average length of time from the onset of symptoms until the
therapy was begun was 14½2 days. He pointed out that when a disease has
progressed more than two-thirds of the way through its natural course
before therapy is started, one is asking a great deal of any therapy, no
matter how efficient, to expect a satisfactory outcome.
Though certain investigators feel that the number of days prior to
therapy does parallel the clinical status when therapy is begun, a more
accurate evaluation can be obtained when one considers both factors. There-
fore, both the length of illness and the classification of the clinical status of
the patient into early, moderate, and late stages of the disease at the time
therapy was initiated has been given. Sixty-five per cent of the patients
were ill two weeks or more prior to the institution of therapy. They were
ill an average of nineteen days, a striking figure when compared with the
average survival of 19½2 days without any therapy. Three of the four
patients who are living received therapy before the fifteenth day. Four of
the patients had one or more relapses. In each instance except one, when
the patient was started on therapy prior to two weeks of illness, the patient
has survived.
Those patients classified as early were those who had no neurological
symptoms, were mainly lethargic, and were completely rational. Only five
patients were in this optimal state when therapy was started. Two of these
five are living. A third patient in this group survived an initial illness and
one relapse, both of which were treated in the early stages, but she died
during the second relapse. On the final admission she was late in the
disease. The moderate patients were lethargic but not semicomatose and
had neurological findings. Ten patients were in this group. They had been
ill from four to fifty-two days. It is, therefore, apparent that there is not an
absolute correlation between clinical status and the duration of illness. One
of these patients has had one relapse returning in the moderate stage of her
illness and has survived that episode. One other patient in this group sur-
vived for over a year but was critically ill when streptomycin was begun
again and died in this relapse. The late patients were semicomatose or
comatose. Twenty-two of the thirty-seven patients were late when therapy
was begun. They had been ill from ten to sixty days. One of these patients is
still under therapy. Another is the son of an itinerant laborer and was re-
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PROVEN CASES OF TUBERCULOUS MENINGrTIS AT RILEY HOSPITAL (1947-1950)
ness Gen- threptomycsn Promi- Life
before eral therapy zole after
Adm. ther- con- Family Mili- Skin Pro- Cui- Guinea I.M. I.T. ther- ther-
No. Pt. date Age apy dition survey X-ray ary test Sugar tein Cells Smear ture pig gm./daymgm./day apy apy Outcome Autopsy
I JW 1-47 2Y 41 L Aunt Mil. + + 18 145 80 - + 0 1 100 - 43D Dead Not granted TBC choroid
2 SO 3-47 9M 7 E Father? Neg. - + 24 66 105 + + 1 100 - 120D Relapse Patient treat
7-47 13M 7 E Neg. - 28 100 27 - + - 1 100 - 186D Relapse Treated 145
2-48 20M 18 L Neg. - 18 82 _- - 2 9 ID Dead Not granted before death.
3 BC 6-47 6Y 21 L Negative Pulm. - + <15 219 225 + + + 2 100 - 8D Dead Not granted
4 MF 7-47 3V2Y 11 E Mother? Pulm. - + 21 61 144 - + - 1 100 - Living
5 JH 8-47 2Y 52 M G-mother Mil. + <15 81 31 - + + 1 8 - 87D Dead Not granted Had receive
mission.
6 WL 8-47 7y2M 15 L G-parents Neg. + + 21 90 74 - + + 2 100 - 2D Dead Mil.&TBC meningitis
7 LD 8-47 6Y 13 L G-father Potts + -1st 22 180 25 - + + 1 - 2D Dead Pulmonary,miliary&
Disease TBC meningitis Died before
8 SW 10-47 6M 39 M Mother Mil. + + 32 42 16 + 2 100 - 120D Dead Not granted
9 PM 11-47 12Y 12 M Negative Pulm. - -1st 25 110 55 + + - 2 100 - 108D Dead Not granted
10 LM 4-48 4V2M 15 M Father Pulm. - + 23 112 13 + - + 2 5 75D Dead Not granted Sibling died
11 EB 5-48 13M 17 L Aunt Pulm. - 0 715 200 96 + 0 2 9 - 16D Dead Not granted
12 BG 8-48 13M 19 L G-father Mil. + + <20 162 92 + 2 9 - ID Dead Pulmonary,miliary&
Pulm. TBC meningitis
13 RH 8-48 2Y 35 L Mother Pulm. - + 23 164 716 + - - 2 10 + 119D ? Signed outb
Brother
14 BV 12-48 liM 27 L Father Mil. + -1st 31 200 74 + - + 1.6 8 + 8D Dead Not granted
15 CH 12-48 17M 15 M Mother? Mil. - 0* <15 122 20 + 2 8 + 5D Dead TBC meningitis and
Sister bronchogenic spread
in lungs
16 KV 12-48 13M 11 M Father Mil. + + <15 180 142 + + 2 10 + 9D Dead Pulmonary,miliary&
TBC meningitis
17 WP 12-48 18M 4 M G-father Mil. 39 105 71 - - 2 25 + 380D Relapse TBC meningitis and Patient treal
1-50 334Y 15 L Healed- + <15 138 108 + + 2 10 + lOlD Dead bronchogenic spread cerbation-tr
in lungs
18 ME 1-49 15M 13 L Uncle Pulm. <15 122 46 - + + 2 ordered - ID Dead Pulmonary,miliary& Died before
+ + TBC meningitis
19 LG 2-49 13M 60 L Father Neg. + + <15 165 113 + + + 2 10 + llD Dead TBC meningitis,
miliary
Comments
Litis
ed 56 days-did well 2M-then relapsed.
days-did well 53-then treated 1 day
Total 332 days.
I lID streptomycin therapy before ad-
intrathecal given.
of TBC meningitis.
'y parents in critical condition.
ted 141 days-did well 9M then re-exa-
reated-lived 93 days-Total 496 days.
intrathecal medication given.Ill-
ness Gen- Streptomycin Promi- Life
before eral therapy zole after
Adm. ther- con- Family Mili- Skin Pro- Cul- Guinea i.m. I.T. ther- ther-
No. Pt. date Age apy dition survey X-ray ary test Sugar tein Cells Smear ture pig gm./day mgm./day apy apy Outcome Autopsy
20 RH 2-49 23/3Y 12 L Aunt Pulm. + 0 <15 1220 107 + 1 10 + 2D Dead Pulmonary,miliary&
TBC meningitis
21 MG 2-49 3'2Y 10 E Sister? Neg. - + <15 64 99 + + 2-4 12 + 423D Relapse Patient trea
5-50 4Y4Y 8 E 0* <15 113 119 - 2 + 116D Dead Not obtained lapse-Trea
601 days.
22 VL 4-49 2Y 10 L Father Neg. - ?lst <15 81 104 - + - 2 - 4D Dead TBC meningitis Died before
23 KF 5-49 4Y 16 E Uncle Pulm. - + <15 120 475 + + + 2 17 + 40D Dead TBC meningitis-
pulmonary
24 JP 5-49 5Y 13 L Negative Pulm. - + <15 64 193 + + 0 2 18 + 30D Dead Not granted
25 JK 6-49 7Y 12 M Mother Neg. - + 17 85 700 - - + 2 + 276D Relapse Treated 59
3-50 7Y/4Y 8 M Neg. - 27 111 280 + + - 2 300D Living Treated 115
26 MM 8-49 8Y 20 L Negative Neg. - + <15 64 99 - + - 2 + 77D Dead Not granted Had craniot
27 MZ 10-49 12Y 12 E Incom- Healed - + <15 74 235 + - + 2 + 94D Dead Not granted
plete Pulm.
28 LH 11-49 13M 11 M Mother Mil. + + <15 94 140 + - - 2 + 49D Dead Pulmonary,miliary&
TBC meningitis
29 BW 4-50 3Y 22 L Incom- Pulm. - + <15 50 84 + + + 2 + lOD Dead Not granted
plete
30 JM 5-50 3Y2Y 47 L Negative Neg. + + 19 197 210 + + + 2 + 13D Dead TBC meningitis-
miliary
31 HH 5-50 12Y 16 L Father 0* - -1st <15 225 318 + + + 2 + 35D Dead Not granted
32 JZ 6-50 lOY 3 E Negative Neg. - + 40 105 384 + + - 2 208D Living Had clinica
+ before adm
and I.T.
33 JD 7-50 20M 40 L G-mother Pulm. - + 16 850 16 + - 2 + 15D Dead TBC meningitis-
pulmonary Block of spi
34 BD 7-50 234Y 25 L Negative Neg. - + <15 58 52 - + - 1 + 5D Dead Not granted Had pulmo
35 JB 8-50 2Y 24 L Brother Neg. - + <15 189 86 + + + 2 + 33D Dead TBC meningitis
36 PJ 10-50 21M 17 L Father? Neg. - + 16 100 3 - + + 1 + 9D Dead Not granted
37 JB 11-50 2Y2Y 19 L Mother Neg. - + <15 159 129 + + + 2 43D Living Still under
Father +
* Not done.
t Table 1 was prepared January 1, 1951. Patients reported alive in this table have remained alive and have had no relapses as of January 1, 1952.
Comments
ted 120 days-did well 10'2M then re-
ted here, then at home 109 days-Total
intrathecal given.
days-did well 7M then relapsed-
days.
tomy.
1 diagnosis of TBC meningitis one year
I. here-treated with streptomycin I.m.
inal canal.
nary TBC 14 months previously.
therapy.TUBERCULOUS MENINGITIS IN CHILDREN
moved against our advice in a critical condition. All efforts to trace the
family and the child have failed. The remainder of this group did not
survive.
Since it was observed that an individual can progress to the late stage of
the disease within ten days or less, it is of importance to consider the latent
period between the time of admission and the institution of therapy. Here,
as elsewhere, the indications for the beginning of streptomycin therapy have
been altered. Early in the studies it was thought that bacteriological proof
must be obtained before streptomycin could be given. Later it was begun
after three spinal fluid examinations; now on clinical impression alone
streptomycin is started, striving for bacteriological proof later.
In those cases where bacteriological proof is not immediately forth-
coming, supporting evidence is derived from the spinal fluid sugar, total
protein, and cell count. In tracing the contact history of the children in this
series, evidence of active tuberculosis was found in an immediate member
of twelve of the families. There was probable tuberculosis in five more
families, but they failed to cooperate with subsequent films and examina-
tions to confirm the initial impression. In eleven families an aunt, uncle, or
grandparent had tuberculosis; in seven it was impossible to establish a
contact history; in two the family survey was admittedly incomplete. There
was good evidence that the contact came from an immediate member of
the family or close relative in 75% of the cases. The Mantoux was positive
intwenty-eight (75%o) of the children. One child had a negative tuberculin;
two died prior to completing the tuberculin test through the second
strength; the record was not complete for the tuberculin reactions on the
other six.
In this laboratory both immediate centrifugation of the spinal fluid as
well as waiting for pellicle formation is utilized; the spinal fluid is cultured
on Lowenstein, Petragnani, and Dubos medium; two spinal fluid samples
and two gastric washing samples are routinely inoculated into guinea pigs.
Fifteen (40%o) of the patients were clinically diagnosed as having miliary
tuberculosis; nine were confirmed at autopsy; another showed residuals of
a disseminated process thought to be compatible with the x-ray diagnosis
of miliary tuberculosis; one diagnosed as miliary tuberculosis during life
was a case of bronchogenic dissemination. In the other four, autopsies were
not granted, though one had tuberculous choroiditis. Ten of the fifteen
lived less than sixteen days.
From January 1, 1947, through April, 1949, streptomycin was given
intramuscularly and intrathecally. The patients received 1 to 2 gms. of
streptomycin intramuscularly daily, except for one patient, MG, who
received 4 gms. of streptomycin daily in a final desperate attempt to save
her life. Therapy was limited to sixty and later 120 days, eventually reach-
ing a point where the clinical condition and the laboratory findings influ-
enced the duration of therapy rather than to have a predetermined length
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of time. Intrathecal dosage varied considerably, ranging from 100 mgm. at
first to 1 mgm. per kilogram body weight before it was discontinued com-
pletely in May, 1949. Intrathecal therapy was given daily unless technical
difficulties prevented the installation of streptomycin. Promizole* was
started in August, 1948, and usually 2 gms. a day were given. A blood level
of 5 mgm. per cent was considered optimum.
We were unable to establish bacteriological proof from the spinal fluid
examinations in fourteen patients (Table 2). Support for the clinical
diagnosis came from the family history which revealed good contact in
eleven cases and probable contact in two more. The chest film was con-
tributory in five cases. The Mantoux was positive in nine cases. Gastric
washings were positive in four. Two patients in this group are living today.
Tuberculous meningitis was confirmed in the four who came to post-
mortem examination.
REVIEW OF LITERATURE
The discouraging results obtained in the series here prompted a survey of
the literature, both in English and in foreign languages. Unfortunately,
much of the literature which has been written on this subject since January,
1946, cannot be readily analyzed, for most series still include unproven
cases and are not reported in a manner facilitating comparative studies. In
doing such an extensive study certain criteria for selection of the cases had
to be established and rigidly followed. Only bacteriologically proven cases
were included; unfortunately, certain series were invalidated, for the
proven cases were mixed with the unproven cases with no possible means
of separating them. The only other factor considered in the selection of the
cases was the age. Only those cases occurring in children under 16 were
included. This age was chosen because the series from here was limited to
children. Table 3 lists the cases with as accurate an analysis of each case as
the report would permit.
One thousand two hundred and twenty cases were found which met the
two criteria. At the time the authors reported their series, 635 were alive,
584 were dead, and the outcome was undetermined from the report of one.
At least 297 had miliary tuberculosis. Inasmuch as the difficulty in
establishing the diagnosis of miliary tuberculosis is well known, it is ap-
parent that the statement in regard to the presence of miliary tuberculosis
cannot be accepted as proven in all cases. Specific age for 1,029 children
was given, with 286 of them being two years or under. From the informa-
tion given about the patients, either in case histories or from tabulation,
580 could be classified as to their clinical status using the criteria employed
earlier in this report; 177 were early in the disease, 235 were moderate, and
* In the early part of this study Promizole was supplied through the courtesy of the
Department of Therapeutic Development, Parke, Davis and Company, Detroit.
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168 were late. Three hundred and thirty-nine patients were ill less than 15
days prior to the onset of therapy; 168 were ill over' 15 days. It was
impossible to determine how long 713 had been ill. For 398 cases in the
series both the duration of the illness and the clinical condition were given.
It is perfectly clear that the two factors are not well correlated, the degree
of variability being so great that it would be most unlikely to have the
situation altered in a larger group. The standard deviation of the number of
days before therapy in each clinical group is so great that considerable over-
lapping is indicated, even though it is not certain that the distribution is
strictly normal.
Since there was great variability in the interval which elapsed from the
time the clinician discontinued therapy until he reported his patients, some
method of comparative study of the cases had to be devised. Four hundred
and thirty-seven children, about whom no essential fact was missing, were
classified as early, moderate, and late in their illness. They were then sub-
divided into various groups-those two years and under; those over two
years; those ill 14 days or less; those ill over 14 days; and those with or
without miliary tuberculosis. If a patient's condition was last reported at
two months, for example, he was then omitted from the statistical calcula-
tion at the third month. Therefore, the accompanying graphs indicate the
known survivors only for a given month expressed in percentage as deter-
mined by dividing the number of known survivors by the number known
living plus the number known dead, i.e., the number whose history was
completely known (Fig. 1).
In all four graphs those patients two years of age and under have been
combined with those over two years. This combination of patients was
justified after subjecting each individual group to a statistical study which
showed that one was not justified in establishing an arbitrary division of
patients at two years and assuming that the prognosis was adversely influ-
enced to a significant degree by the younger age. The method employed in
this study was the application of the Chi squared test to a contingency table
of monthly survival totals.
The same method was used in the following analysis of the data. Figure
1, Graph A, shows the number of patients reported as surviving at each
specific month for a 24-month period. These were the patients who were
not reported as having miliary tuberculosis and were started on therapy in
less than 15 days from the onset of their illness. This group of patients with
the most favorable circumstances was compared with the remaining group,
i.e., those who were started on therapy after the second week of illness
(those in Graph B) and those who had miliary tuberculosis (those in
Graphs C and D). A significantly high Chi squared figure was obtained
showing that those in our presumptively most favorable Group A actually
did have a better prognosis than the remainder of the series.
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FIG. 1. Percentage of known survivors in the literature with the most complete data.
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All those patients with miliary tuberculosis were compared with all those
without miliary tuberculosis. It was found that the two groups did not show
a significant variation from each other in month-by-month survival. A more
minute analysis by clinical condition, i.e., early, moderate, and late stages of
the disease, revealed significant differences between the miliary and non-
miliary cases in the moderate and late groups, but any difference in the
early group could not be proven to be free from chance. The therapy can be
grouped into three general categories:
1,220 Patients
IM + IT Streptomycin plus
IM + IT Streptomycin adjunct therapy Miscellaneous therapy
657 Patients 521 Patients 42 Patients
Promizole ............ 21 Im Streptomycin ... 29
Sulphetrone-Streptokinase . 34 IM Streptomycin
Promin (Promine) ....... 161 Promin .......... 2
Sulfone ............ 99 IT Streptomycin .... 7
Tuberculin ............ 159 Unknown .......... 4
PPD ....... ..... 12
Streptokinase .............. 6 42
PAS ....... ..... 3
Sulfone-Dicumerol ....... 1
Sulfone or PAS .......... 25
521
The 657 patients who received only intramuscular plus intrathecal
streptomycin were compared with the 521 who received intramuscular plus
intrathecal streptomycin with some adjunct therapy. Variation in the total
dosage and the frequency of administration could not be taken into con-
sideration because of the extreme complexity of the over-all therapeutic
regime. It was found that there was no significant difference between the
two groups as a whole. However, when those receiving a sulfone were
removed from the total number receiving adjunct therapy and then com-
pared with those receiving intramuscular plus intrathecal streptomycin, it
was observed that the administration of a sulfone favorably influenced the
outcome in the first few months after the administration of the medication.
As time progressed, those receiving a sulfone actually faired less well as a
group. Those receiving tuberculin which had been given intravenously
reversed the pattern, showing a significantly adverse reaction to the
tuberculin in the early months, but later on this effect disappeared and those
receiving tuberculin did somewhat better after the sixth month. When those
receiving intramuscular streptomycin alone were compared with those
receiving intramuscular and intrathecal streptomycin without an adjunct,
the variation was of no importance.
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DISCUSSION
The authors recognize that certain errors in tabulation may have been
introduced into this study. A genuine effort was made to obtain all the
proven cases of tuberculous meningitis in children recorded in the litera-
ture since streptomycin was introduced as a therapeutic agent. It is surely
obvious that this effort was unsuccessful to some degree for reasons which
are apparent. From the onset of this work it was evident that lack of uni-
formity in reporting, even as to what might be called a therapeutic success,
was to plague us as the various aspects of the over-all problem were
analyzed. For this reason the method of the Chi squared test applied to
contingency tables of monthly survival totals pervades all the principal
calculations.
The history of the development of the present-day therapy for the
purulent meningitides is an interesting one. When type specific antisera
were first employed, they were introduced intrathecally in a therapeutic
gesture. It was observed later that the patient's recovery was not adversely
influenced if the serum was not placed directly into the central nervous
system, and that actually many of the sequelae attributed to the severity of
the disease were being caused by this route of administration, and that if
the serum was given intravenously or intramuscularly alone, the patient had
a greater opportunity for complete recovery. When the chemotherapeutic
and the antibiotic agents were first used, they too were introduced
intrathecally.
Actually, it is just recently that most physicians have discontinued the
intrathecal administration of penicillin in pneumococcal meningitis, and of
streptomycin in Hemophilus influenzae, type b, meningitis. There can be
no doubt that this transition has not as yet taken place in the treatment of
tuberculous meningitis, for only thirty-one out of the 1,220 patients received
intramuscular treatment without intrathecal treatment.
At this hospital the children received intramuscular and intrathecal
streptomycin therapy until May, 1949, at which time all intrathecal admin-
istration was discontinued. This change in therapy was initiated because
data had been accumulating to indicate that significant streptomycin levels
were obtained in the spinal fluid from intramuscular streptomycin alone;
certain serious complications from the intrathecal injection of streptomycin
were being observed, and the rare case given intramuscular streptomycin
alone had been reported as doing satisfactorily. Though more of the sur-
vivors from this hospital appear in the series receiving intramuscular
streptomycin alone, the number is too small to be of significance.
The length of survival of those under two years of age was compared
with that observed in those over two years old receiving treatment in this
hospital. Those under two had a shorter survival time than those over two.
This was attributed to the presence of other adverse circumstances found in
the younger children, namely, the greater length of time before the patient
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was brought to the hospital for therapy, the more serious clinical condition,
and the more frequent presence of miliary tuberculosis. This fact could not
be directly compared with the observations made in the literature because
those tables had to be established on the percentage of survivals reported.
From the literature it was of no significance to establish an arbitrary
dividing point at the age of two years, yet it was possible to show that each
individual factor being brought to bear upon the child under two was exert-
ing a deleterious influence. Perhaps inability to prove this difference in
response from the literature may be explained by the natural tendency to
report therapeutic successes rather than failures; therefore, the figures may
be inadvertently weighted.
In both this series and in the literature there was good evidence that the
duration of illness inversely influenced the outcome. This would seem obvi-
ous. But when the duration of illness was compared with the clinical status,
there was little correlation, and it could be shown that the clinical status of
the patient at the time of therapy was instituted was of great significance in
determining the ultimate outcome.
The presence of miliary tuberculosis adversely influenced the patients
seen in this hospital. When the large group was studied, it was surprising
to find that the presence of miliary tuberculosis does not influence the out-
come if the patient comes to therapy early in the disease, but in the later
stages miliary tuberculosis materially alters the outcome. This may be
explained by the medication favorably influencing the disseminated disease
early in its course, but once it has become well established, medication can-
not reverse the process. It should be stated that in the interpretation of the
graphs for the influence of miliary tuberculosis on the outcome, the early
cases in Graph D were not included because the number of patients was
too small.
The beneficial influence of sulfone therapy is interesting in light of the
observations of Lincoln5" on the favorable influence Promizole had upon
children with miliary tuberculosis alone. It is tenable that the two drugs,
streptomycin and a sulfone, do complement each other to the patient's
advantage. It is difficult to explain the apparent late adverse effect of the
sulfones on the ratio of the survivors.
The early adverse influence of intravenous tuberculin was not anticipated.
One can speculate that the tuberculin served to "light up" the tuberculous
process to so great a degree that the patient was unable to handle the
additional insult.
Though it could be shown that there was no variation beyond that intro-
duced by chance in the comparison of the survival totals for the patients
receiving intramuscular streptomycin alone and those receiving intramuscu-
lar plus intrathecal streptomycin, it is impossible to accept this as a valid
observation, since the total group receiving intramuscular streptomycin
alone was too small.
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SUMMARY
Forty-one additional proven cases have been added to the literature.
After April, 1949, no patient with tuberculous meningitis at this hospital
has received intrathecal medication.
One thousand two hundred and twenty cases of proven tuberculous
meningitis in children have been analyzed.
It was possible to demonstrate that those children under two years of age
had a poor prognosis from this series, but an arbitrary delineation at the
age of two could not be established in those cases taken from the literature.
An explanation for this is offered.
The clinical status of the patient is of more value than the duration of
illness in estimating the prognosis.
Miliary tuberculosis was shown to influence adversely those who were
moderately ill and those who were late in their illness, but it was not possi-
ble to demonstrate that it exerted an adverse influence in those treated early.
Sulfones favorably influenced the early outcome of the patients studied in
the literature.
Intravenous tuberculin adversely influenced the early outcome of the
patients studied in the literature.
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